FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1075-1079 April 8, 1999 Number 14 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The occurrence of symptomatic central hypothyroidism (characterized by low serum thyrotropin and thyroxine concentrations) in a patient with cutaneous T-cell lymphoma during therapy with the retinoid X receptor–selective ligand bexarotene led us to hypothesize that such ligands could reversibly suppress thyrotropin production by a thyroid hormone–independent mechanism and thus cause central hypothyroidism.

Methods We evaluated thyroid function in 27 patients with cutaneous T-cell lymphoma who were enrolled in trials of high-dose oral bexarotene at one institution. In addition, we evaluated the in vitro effect of triiodothyronine, 9-cis-retinoic acid, and the retinoid X receptor–selective ligand LGD346 on the activity of the thyrotropin ß-subunit gene promoter.

Results The mean serum thyrotropin concentration declined from 2.2 mU per liter at base line to 0.05 mU per liter during treatment with bexarotene (P<0.001), and the mean serum free thyroxine concentration declined from 1.0 ng per deciliter (12.9 pmol per liter) at base line to 0.45 ng per deciliter (5.8 pmol per liter) (P<0.001) during treatment. The degree of suppression of thyrotropin secretion tended to be greater in patients treated with higher doses of bexarotene (>300 mg per square meter of body-surface area per day) and in those with a history of treatment with interferon alfa. Nineteen patients had symptoms or signs of hypothyroidism, particularly fatigue and cold intolerance. The symptoms improved after the initiation of thyroxine therapy, and all patients became euthyroid after treatment with bexarotene was stopped. In vitro, LGD346 suppressed the activity of the thyrotropin ß-subunit gene promoter in thyrotrophs by as much as 50 percent, an effect similar to that of triiodothyronine and 9-cis-retinoic acid.

Conclusions Hypothyroidism may develop in patients with cutaneous T-cell lymphoma who are treated with high-dose bexarotene, most likely because the retinoid X receptor–selective ligand suppresses thyrotropin secretion.

Source Information

From the Sections of Endocrine Neoplasia and Hormonal Disorders (S.I.S., J.G., A.C.C.) and Dermatology (K.W., P.N., M.D.), University of Texas M.D. Anderson Cancer Center, Houston; and the Division of Endocrinology, University of Colorado Health Sciences Center, Denver (B.R.H.).

Address reprint requests to Dr. Sherman at the University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 15, Houston, TX 77030, or at sisherma{at}mdanderson.org.

Full Text of this Article

This article has been cited by other articles:

• Zimmermann, M. B, Jooste, P. L, Mabapa, N. S., Schoeman, S., Biebinger, R., Mushaphi, L. F, Mbhenyane, X. (2007). Vitamin A supplementation in iodine-deficient African children decreases thyrotropin stimulation of the thyroid and reduces the goiter rate. Am. J. Clin. Nutr. 86: 1040-1044 [Abstract] [Full Text]  
• Smit, J. W. A., Stokkel, M. P. M., Pereira, A. M., Romijn, J. A., Visser, T. J. (2007). Bexarotene-Induced Hypothyroidism: Bexarotene Stimulates the Peripheral Metabolism of Thyroid Hormones. J. Clin. Endocrinol. Metab. 92: 2496-2499 [Abstract] [Full Text]  
• Biebinger, R., Arnold, M., Langhans, W., Hurrell, R. F., Zimmermann, M. B. (2007). Vitamin A Repletion in Rats with Concurrent Vitamin A and Iodine Deficiency Affects Pituitary TSH{beta} Gene Expression and Reduces Thyroid Hyperstimulation and Thyroid Size. J. Nutr. 137: 573-577 [Abstract] [Full Text]  
• Golden, W. M., Weber, K. B., Hernandez, T. L., Sherman, S. I., Woodmansee, W. W., Haugen, B. R. (2007). Single-Dose Rexinoid Rapidly and Specifically Suppresses Serum Thyrotropin in Normal Subjects. J. Clin. Endocrinol. Metab. 92: 124-130 [Abstract] [Full Text]  
• Liu, Y. Y, Stokkel, M. P, Pereira, A. M, Corssmit, E. P, Morreau, H. A, Romijn, J. A, Smit, J. W A (2006). Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.. Eur J Endocrinol 154: 525-531 [Abstract] [Full Text]  
• Sharma, V., Hays, W. R., Wood, W. M., Pugazhenthi, U., St. Germain, D. L., Bianco, A. C., Krezel, W., Chambon, P., Haugen, B. R. (2006). Effects of Rexinoids on Thyrotrope Function and the Hypothalamic-Pituitary-Thyroid Axis. Endocrinology 147: 1438-1451 [Abstract] [Full Text]  
• Leibowitz, M. D., Ardecky, R. J., Boehm, M. F., Broderick, C. L., Carfagna, M. A., Crombie, D. L., D'Arrigo, J., Etgen, G. J., Faul, M. M., Grese, T. A., Havel, H., Hein, N. I., Heyman, R. A., Jolley, D., Klausing, K., Liu, S., Mais, D. E., Mapes, C. M., Marschke, K. B., Michellys, P.-Y., Montrose-Rafizadeh, C., Ogilvie, K. M., Pascual, B., Rungta, D., Tyhonas, J. S., Urcan, M. S., Wardlow, M., Yumibe, N., Reifel-Miller, A. (2006). Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes. Endocrinology 147: 1044-1053 [Abstract] [Full Text]  
• Schaiff, W. T., Bildirici, I., Cheong, M., Chern, P. L., Nelson, D. M., Sadovsky, Y. (2005). Peroxisome Proliferator-Activated Receptor-{gamma} and Retinoid X Receptor Signaling Regulate Fatty Acid Uptake by Primary Human Placental Trophoblasts. J. Clin. Endocrinol. Metab. 90: 4267-4275 [Abstract] [Full Text]  
• Rigas, J. R., Dragnev, K. H. (2005). Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene. The Oncologist 10: 22-33 [Abstract] [Full Text]  
• Haugen, B. R., Jensen, D. R., Sharma, V., Pulawa, L. K., Hays, W. R., Krezel, W., Chambon, P., Eckel, R. H. (2004). Retinoid X Receptor {gamma}-Deficient Mice Have Increased Skeletal Muscle Lipoprotein Lipase Activity and Less Weight Gain when Fed a High-Fat Diet. Endocrinology 145: 3679-3685 [Abstract] [Full Text]  
• Ogilvie, K. M., Saladin, R., Nagy, T. R., Urcan, M. S., Heyman, R. A., Leibowitz, M. D. (2004). Activation of the Retinoid X Receptor Suppresses Appetite in the Rat. Endocrinology 145: 565-573 [Abstract] [Full Text]  
• Esteva, F. J., Glaspy, J., Baidas, S., Laufman, L., Hutchins, L., Dickler, M., Tripathy, D., Cohen, R., DeMichele, A., Yocum, R. C., Osborne, C. K., Hayes, D. F., Hortobagyi, G. N., Winer, E., Demetri, G. D. (2003). Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer. JCO 21: 999-1006 [Abstract] [Full Text]  
• Aboulafia, D. M., Norris, D., Henry, D., Grossman, R. J., Thommes, J., Bundow, D., Yocum, R. C., Stevens, V. (2003). 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma: Results of a Phase 2 Multicenter Clinical Trial. Arch Dermatol 139: 178-186 [Abstract] [Full Text]  
• McDermott, N. B., Gordon, D. F., Kramer, C. A., Liu, Q., Linney, E., Wood, W. M., Haugen, B. R. (2002). Isolation and Functional Analysis of the Mouse RXRgamma 1 Gene Promoter in Anterior Pituitary Cells. J. Biol. Chem. 277: 36839-36844 [Abstract] [Full Text]  
• Lippman, S. M., Hong, W. K. (2002). Cancer Prevention Science and Practice. Cancer Res. 62: 5119-5125 [Full Text]  
• Liu, S., Ogilvie, K. M., Klausing, K., Lawson, M. A., Jolley, D., Li, D., Bilakovics, J., Pascual, B., Hein, N., Urcan, M., Leibowitz, M. D. (2002). Mechanism of Selective Retinoid X Receptor Agonist-Induced Hypothyroidism in the Rat. Endocrinology 143: 2880-2885 [Abstract] [Full Text]  
• Macchia, P. E., Jiang, P., Yuan, Y.-D., Chandarardna, R. A. S., Weiss, R. E., Chassande, O., Samarut, J., Refetoff, S., Burant, C. F. (2002). RXR receptor agonist suppression of thyroid function: central effects in the absence of thyroid hormone receptor. Am. J. Physiol. Endocrinol. Metab. 283: E326-E331 [Abstract] [Full Text]  
• Yen, P. M. (2001). Physiological and Molecular Basis of Thyroid Hormone Action. Physiol. Rev. 81: 1097-1142 [Abstract] [Full Text]  
• Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C. (2001). Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results. JCO 19: 2456-2471 [Abstract] [Full Text]  
• Duvic, M., Martin, A. G., Kim, Y., Olsen, E., Wood, G. S., Crowley, C. A., Yocum, R. C., for the Worldwide Bexarotene Study Group, (2001). Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma. Arch Dermatol 137: 581-593 [Abstract] [Full Text]  
• Cheng, S. X., Kupper, T. (2001). A New Rexinoid for Cutaneous T-Cell Lymphoma. Arch Dermatol 137: 649-652 [Full Text]  
• Venihaki, M., Carrigan, A., Dikkes, P., Majzoub, J. A. (2000). Circadian rise in maternal glucocorticoid prevents pulmonary dysplasia in fetal mice with adrenal insufficiency. Proc. Natl. Acad. Sci. USA 97: 7336-7341 [Abstract] [Full Text]  
• Lippman, S. M., Brown, P. H. (1999). Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost. JNCI J Natl Cancer Inst 91: 1809-1819 [Full Text]